Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (134 reviews)

For research use only.

Catalog No.S1091

134 publications

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 134 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01028-8

PubMed: 33403501 ( click the link to review the publication )

Cell Signal, 2021, 80:109911

PubMed: 33422645 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)621

PubMed: 33557316 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Theranostics, 2020, 10(26):12204-12222

PubMed: 33204338 ( click the link to review the publication )

Cell Rep, 2020, 33(3):108293

PubMed: 33086062 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3717

PubMed: 33322337 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Mol Neurobiol, 2020, 57(3):1570-1593

PubMed: 31797328 ( click the link to review the publication )
Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 44(4):1649-1661

PubMed: 32945502 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biol Pharm Bull, 2020, 10.1248/bpb.b20-00362

PubMed: 32863294 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Aging Cell, 2019, 18(3):e12932

PubMed: 30884121 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )
J Agric Food Chem, 2019, 67(34):9510-9521

PubMed: 31382738 ( click the link to review the publication )

Biochimie, 2019, 163:108-116

PubMed: 31185266 ( click the link to review the publication )

Mol Med Rep, 2019, 19(4):2825-2830

PubMed: 30720075 ( click the link to review the publication )

Exp Ther Med, 2019, 17(3):1663-1669

PubMed: 30867686 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Genes Dev, 2018, 32(13-14):915-928

PubMed: 29945888 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Mol Cancer, 2018,

PubMed: 29455661 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Cell Signal, 2018, 52:12-22

PubMed: 30138697 ( click the link to review the publication )
PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4014-4025

PubMed: 28619711 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28534511 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Mol Cancer Res, 2017,

PubMed: 28289161 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2364

PubMed: 28539593 ( click the link to review the publication )

Endocrinology, 2017,

PubMed: 29028997 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28002807 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )
Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

Mol Cancer, 2015,

PubMed: 26041671 ( click the link to review the publication )

J Bone Miner Res, 2015, 30(11):1959-68

PubMed: 25990470 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cancer Res, 2015,

PubMed: 26263910 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116895

PubMed: 25603314 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26515601 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )
Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Neoplasia, 2014, 16(10):824-34

PubMed: 25379019 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
A4-Fuk	NYewTFhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF7YSmRKSzVyPUCuNFI5ODZizszN	MlLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KS-1	M2Pnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHixbZhKSzVyPUCuNFM5OzVizszN	NE\aNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TE-11	M2\CdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MknPTWM2OD1yLkC3PFIzKM7:TR?=	NHz4SmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
EW-1	M3XCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkP4TWM2OD1yLkC4OVg2KM7:TR?=	NV;sTZFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HMV-II	NG\WSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEHIcXNKSzVyPUCuNFg5PDZizszN	MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-205	NWrhXHBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlHMTWM2OD1yLkGwOFU1KM7:TR?=	NV3PfnFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ES1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{\YfWlEPTB;MD6xNFY6PiEQvF2=	NVHHcIc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GDM-1	NGHvdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4DNRmlEPTB;MD6xN\|Y4OiEQvF2=	NEO4W2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ML-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVXJR\|UxRTBwMUW4PVYh\|ryP	M1XBNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
Saos-2	NVXGdYxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUe1e5RSUUN3ME2wMlE3PTJ4IN88US=>	NWflXYlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1355	NGfTPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4XQZ2lEPTB;MD6xPFE{PSEQvF2=	NHm0bZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
G-401	NGnBdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVfJR\|UxRTBwMUiyN{DPxE1?	Mo\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-16	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3TNW2lEPTB;MD6xPFc4PyEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EW-7	NXSzRYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVjJR\|UxRTBwMUi4PFEh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H727	M1HzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3zPeGlEPTB;MD6xPVc6PCEQvF2=	MkCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LCLC-97TM1	M{\NfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXHJR\|UxRTBwMkC5OVUh\|ryP	NWD6fYFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H650	NELEfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUPJR\|UxRTBwMkGzPFQh\|ryP	NVvSXlgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2122	NEjacVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlH1TWM2OD1yLkKzNlk6KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	NInMR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY[1RZI5UUN3ME2wMlI{Pjl6IN88US=>	NHn1SYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HT-29	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3QN4cxUUN3ME2wMlI1OjR6IN88US=>	NXfEWlNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB771-HNC	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXjJR\|UxRTBwMkW5NVUh\|ryP	NWDYc4I6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HT-144	NWTlWndtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYTjWpVqUUN3ME2wMlI3OTlzIN88US=>	NXrFcJBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LAN-6	NGDKfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFezNGlKSzVyPUCuNlY{PDhizszN	NHTrRmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
EW-18	M{Lib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX7JR\|UxRTBwMkewNFEh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LS-1034	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnjBTWM2OD1yLkK3NVMzKM7:TR?=	M2DmflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EW-11	NFvSeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUKwOYlSUUN3ME2wMlI5PDN{IN88US=>	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNU-C1	M4\WcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYjJR\|UxRTBwMkmzNVMh\|ryP	M{HrblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
RS4-11	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFzITY9KSzVyPUCuN\|M4PThizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES4	NXz4W3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGH5SHZKSzVyPUCuOFExOzhizszN	NYfvOmJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
COLO-320-HSR	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1HNOWlEPTB;MD60NVM3QCEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NB10	NXnvbolxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlvwTWM2OD1yLkS1OFM4KM7:TR?=	M3H6fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BFTC-905	M3;nfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH7z[Y9KSzVyPUCuOFY4PThizszN	NHPjZWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A375	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoLBTWM2OD1yLkS3OlE4KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SJRH30	NXf3Z5RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVS5[mYzUUN3ME2wMlUxQDJ{IN88US=>	NUX1[HNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NOS-1	NXT5e2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3OxW2lEPTB;MD61NlI3PyEQvF2=	NV7IeHFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SIG-M5	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2TzTmlEPTB;MD61N\|U2PyEQvF2=	M2LLcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
DOK	M1:3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWfBOoV5UUN3ME2wMlU2PiEQvF2=	NF3BZWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB69	NWr4SWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4nYfGlEPTB;MD61PFI2PyEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NUGzUIlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MofvTWM2OD1yLk[wNlM3KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MM-2	NYD2TmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1PaXmlEPTB;MD62OVQ6OSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H358	NUS4OZp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWfJR\|UxRTBwNkewPFIh\|ryP	M2XhblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
RH-1	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NG[yXppKSzVyPUCuO\|Q5PTlizszN	NF\STlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NH-12	NWnpfYRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXTJR\|UxRTBwN{[wOFYh\|ryP	M2LmRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-12	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MULJR\|UxRTBwN{[0PFYh\|ryP	M2n0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-668	NWPxd5h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUDJR\|UxRTBwOES2OlYh\|ryP	M2PnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PANC-08-13	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfzW3ZrUUN3ME2wMlg3Ozd5IN88US=>	MkfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HCC2998	NVvzZYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX;JR\|UxRTBwOEiyOlMh\|ryP	NVn6e5hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ABC-1	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH70UHdKSzVyPUCuPVA{PTJizszN	NV\qcGlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ES6	NFzsNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLH[olKSzVyPUCuPVExPjZizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SNU-387	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHOxWpBKSzVyPUCuPVk{QTNizszN	NFLpe3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CMK	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVXJR\|UxRTBwOUm5Nlkh\|ryP	M1jjWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SJSA-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mk[xTWM2OD1zLkCzOlU{KM7:TR?=	NUnsfXRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SIMA	NG\ESG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkLtTWM2OD1zLkC2PFI2KM7:TR?=	M3PrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ES3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFyxc3hKSzVyPUGuNVIzQTdizszN	MkTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
IGROV-1	NXfHVmlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1e0ZWlEPTB;MT6xOVQ1PCEQvF2=	MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MEL-JUSO	NWP6foYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUTJR\|UxRTFwMUW3OVkh\|ryP	NID3TXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
T84	NIixTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF[3fnRKSzVyPUGuNlA6OTRizszN	M3PxbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CAL-85-1	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVLJR\|UxRTFwMkOxN\|gh\|ryP	M1L0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
RD	NWfMU2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mmr0TWM2OD1zLkK2OFU2KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TE-8	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVvJR\|UxRTFwM{G0OlIh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
L-363	NHPh[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoHZTWM2OD1zLkO0NlA5KM7:TR?=	NW\ufI1DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EKVX	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTYd5lKSzVyPUGuN\|Q2PjhizszN	NUSyTXFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-MEL-3	M4LMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkDuTWM2OD1zLkS4OVU3KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	M1;VXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVrm[YRLUUN3ME2xMlUxOTl\|IN88US=>	Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1770	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mmn1TWM2OD1zLkWxNVE{KM7:TR?=	M{XPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HuH-7	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M361RmlEPTB;MT62NFA6QCEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HL-60	M1voOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG\nNJFKSzVyPUGuOlY6OjhizszN	M3nVc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF3lUWhKSzVyPUGuO\|A6PDVizszN	M3HmeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LC-2-ad	M1TCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoraTWM2OD1zLkezPFg4KM7:TR?=	NILMfVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LB647-SCLC	NEW2UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NULBdG1[UUN3ME2xMlc3PTh\|IN88US=>	Mk\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2171	Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkjxTWM2OD1zLke3O\|E3KM7:TR?=	NWDTWWtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-PN-DW	M1L1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrvTWM2OD1zLkmxNlk5KM7:TR?=	NHH0[nQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MC-IXC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NITsfIhKSzVyPUGuPVg6QCEQvF2=	M2PwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LS-513	NUTJb4FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUT4ZYxoUUN3ME2yMlA2OzB3IN88US=>	NXPRPGFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EW-3	NXvhbFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF\VN4hKSzVyPUKuNFk5PDRizszN	NHLJNVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OPM-2	M13sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmXHTWM2OD1{LkGwNkDPxE1?	Mn;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LP-1	M37ETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWLJR\|UxRTJwMkW4NFch\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LU-134-A	NInDNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVGwb5FSUUN3ME2yMlI4PyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CP66-MEL	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEK0eoFKSzVyPUKuNlkxOTRizszN	NV:zRXRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HCC1143	NYj0PVRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXixfpJ4UUN3ME2yMlQ2OzZ6IN88US=>	NHvCXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LOXIMVI	NXzT[3plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDzTWM2OD1{Lk[wNlEh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TE-10	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWnJR\|UxRTJwN{C4N\|gh\|ryP	NGH2Oos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1882	NUXr[JQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYG5V5J4UUN3ME2yMlc2OjJ5IN88US=>	NELPUo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CHP-126	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEDDUmJKSzVyPUKuO\|Y{OTdizszN	MlvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1623	NXHN[pJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWfJR\|UxRTJwOUKwNlQh\|ryP	NXPIN4EyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVPJR\|UxRTJwOUO0NFQh\|ryP	NXHpeW1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RCC10RGB	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF\DVYxKSzVyPUKuPVUzQDFizszN	MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2141	M17afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;JVGxYUUN3ME2yMlk3QDl4IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GI-ME-N	NEm2dmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWflUpdCUUN3ME2zMlAxPTZ3IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H526	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYTJR\|UxRTNwMESwPFUh\|ryP	NH\jN2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H747	NHnQcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NW\kcW4yUUN3ME2zMlA1QTl{IN88US=>	NWTHUFI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNU-423	NHOxb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlrMTWM2OD1\|LkKwN\|E{KM7:TR?=	M2TIN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A427	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\XPGNKSzVyPUOuNlU3QTlizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CAL-12T	M17DZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYfJR\|UxRTNwNEC3NVMh\|ryP	NFq5dlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LU-99A	NHLURpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEHtNmRKSzVyPUOuOFcyODVizszN	NH\FW2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MS-1	NU\SOJpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTWPWdKSzVyPUOuOVM1OjlizszN	Mmm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-LU-1	M3zvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF;UTFFKSzVyPUOuO\|YzQTVizszN	NU[zSlBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW837	NH3XW\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlznTWM2OD1\|Lke2N\|M{KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES8	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3nxfmlEPTB;Mz64N\|g4PyEQvF2=	NHHwUIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MZ2-MEL	NWnROWtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3\HRmlEPTB;Mz65NlA5PiEQvF2=	NXfWZZhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
TGW	NIDQcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYn1Smg4UUN3ME20MlAyOzFzIN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GP5d	NFe3XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUS4dZBCUUN3ME20MlA2OzZ{IN88US=>	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BB49-HNC	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnyxTWM2OD12LkG1NlE{KM7:TR?=	M3jSUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NB13	NH\LeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1TPNGlEPTB;ND6yOlg5PyEQvF2=	NHLpPZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NTERA-S-cl-D1	NF7QPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX:xN2JTUUN3ME20MlI5PjF3IN88US=>	NEP1Omo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1648	NYTuVYpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXLPb3ZsUUN3ME20MlI6QDF7IN88US=>	Mn7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LCLC-103H	NITNWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkDHTWM2OD12LkOyNVk2KM7:TR?=	NVfNTohsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LS-411N	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmHETWM2OD12LkS0PFg2KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1092	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{ficWlEPTB;ND60OVY5PyEQvF2=	M{TGNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PANC-10-05	MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\3TYVbUUN3ME20MlY6QDRizszN	NInxZWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DK-MG	NETTUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUP3dJh[UUN3ME20MlgxQTN\|IN88US=>	NWq2e2tSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
OVCAR-5	NVfwdFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWTJR\|UxRTRwOEGyNlYh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CAL-39	NYPjNYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFLOU4ZKSzVyPUSuPFc3PyEQvF2=	MlTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TE-441-T	NUDBO5B1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGHEW4pKSzVyPUSuPVA2OzdizszN	M2\3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MOLT-16	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zWTGlEPTB;ND65OVI2OyEQvF2=	M3fhdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MCF7	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYnJR\|UxRTVwMUS1NVch\|ryP	NH7lSYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAPAN-1	NE\FNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUXJR\|UxRTVwMkW3NFch\|ryP	NWf6TY5FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PSN1	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFHFcGVKSzVyPUWuNlczOzVizszN	NX3ncFM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H292	NGT5S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX7JR\|UxRTVwM{CwOFQh\|ryP	NF\TUZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CPC-N	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVvDRWR2UUN3ME21MlM6PDF7IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DoTc2-4510	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHiyW2lKSzVyPUWuOFU{PzFizszN	NWOxPYFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB1047-RCC	NUTxRYw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4fwZ2lEPTB;NT61OVk{OyEQvF2=	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MHH-ES-1	M4KzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIraZXJKSzVyPUWuOVk6ODdizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NMC-G1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfqZllKSzVyPUWuO\|AzOjdizszN	NX7LPVJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW1710	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NITSXpFKSzVyPUWuO\|Q4PTFizszN	MnnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
YAPC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXnJR\|UxRTVwN{[yNFEh\|ryP	NIThSnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
22RV1	NUTO[ZZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF7HTYxKSzVyPUWuPFAxOTlizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COLO-679	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVjJR\|UxRTVwOEi5OFgh\|ryP	NHfZWmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TCCSUP	NGPHW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYDac2pKUUN3ME21Mlk{OjV7IN88US=>	NFvXb4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
C2BBe1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzRTWM2OD13LkmzPVch\|ryP	NHrBNWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TE-15	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3LleGlEPTB;Nj6wOlYxPSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SCLC-21H	NXTWW3BIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWDJR\|UxRTZwMUC4OFMh\|ryP	NV62VWsxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EoL-1-cell	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MojQTWM2OD14LkG2OVY{KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NKM-1	NITDXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUXiRXlQUUN3ME22MlE3PzFizszN	MlP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1304	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFezSlBKSzVyPU[uNlc1OjhizszN	NVTLZpZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NB6	NEj6d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MofNTWM2OD14LkK5OlIzKM7:TR?=	NUnST2JRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NALM-6	NWXYN2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHvqW3BKSzVyPU[uN\|MzOyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H522	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn3TTWM2OD14LkOzN\|A3KM7:TR?=	M2PJU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MV-4-11	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoSyTWM2OD14LkO3NFc6KM7:TR?=	M3HsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LB2241-RCC	M37X[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYPJR\|UxRTZwM{i2Olch\|ryP	NH23eWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1417	NGfBVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4XzUWlEPTB;Nj60NFg1PyEQvF2=	M2rkeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HT-1197	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF;oS3pKSzVyPU[uOVcyOjJizszN	M12yTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
P30-OHK	NYPMOGF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{jZUWlEPTB;Nj62Nlc4KM7:TR?=	NILySXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ALL-PO	NH7ufIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF:yXHdKSzVyPU[uO\|E6OTZizszN	M{G4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
OVCAR-4	NV;UNIozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2TJSGlEPTB;Nj63OVQxPSEQvF2=	MojCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HCC2157	Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVXGe5hSUUN3ME22Mlc4PDd3IN88US=>	NEHHU3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H838	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGfrbINKSzVyPU[uPVY1QSEQvF2=	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1299	NH;5VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV\oRnM1UUN3ME22Mlk4ODlizszN	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW954	NV;PZ3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4O0RmlEPTB;Nz6yNFA3QCEQvF2=	M1PPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H441	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfXXVhvUUN3ME23MlM1ODZ3IN88US=>	NIfJfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-MEL-2	NEDDXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2rv[GlEPTB;Nz60PFM4OyEQvF2=	NUjNfJpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KARPAS-45	M3HOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHTU[llKSzVyPUeuOlU6OjlizszN	NFe4V5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAL-54	Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XVTWlEPTB;Nz64Nlk4PyEQvF2=	NFy0SVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-180	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVzJR\|UxRTdwOEi5OFEh\|ryP	M{LZbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H187	NWDHWoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUXGfFBjUUN3ME23Mlk2QTR5IN88US=>	Ml;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
RT-112	M{G2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGW1[WxKSzVyPUiuNFk3PzdizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1437	NULNOHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2HpW2lEPTB;OD6wPVc6PSEQvF2=	NFTIb3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SNU-449	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfuU2hKSzVyPUiuNlgzPzJizszN	NUS1UYNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HCC1187	M2fYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXLJR\|UxRThwMkmzPVEh\|ryP	M4H4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2030	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXrIN2F1UUN3ME24MlM4PzF2IN88US=>	NVvhRmVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HuO-3N1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYLxRo9WUUN3ME24MlM4QDR2IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COLO-792	M2fKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEfVXVhKSzVyPUiuOFE2OjdizszN	NXzPTGNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MIA-PaCa-2	NUXSUmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEjkd4lKSzVyPUiuPFU2ODhizszN	NIPBWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-N-FI	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnnPTWM2OD17LkC0NlUh\|ryP	NW\Q[JpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MMAC-SF	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU\JR\|UxRTlwMEm3OVEh\|ryP	NHvaenc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H28	M3fqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIi2[HlKSzVyPUmuNVA1PjlizszN	M3zRRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ETK-1	NI[1W\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHmTWM2OD17LkK5PVc1KM7:TR?=	NEHK[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1993	NF3aNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVLJR\|UxRTlwNESyOlEh\|ryP	NVnhUGFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
no-11	NUThb3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVfJR\|UxRTlwNEexNkDPxE1?	M3zXSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ChaGo-K-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGHvcIhKSzVyPUmuOVE2QDNizszN	NXm3TWtERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCCIT	NGXvdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlzaTWM2OD17LkWzNVY6KM7:TR?=	NUO1[nhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SAS	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWfsUWZ5UUN3ME2xNE4zPDhizszN	M1O4N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A673	NWjs[3RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlzZTWM2OD1zMD6zO\|A1KM7:TR?=	MmfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1522	NED2PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH65UpdKSzVyPUGwMlM4ODdizszN	NEnxZ\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H810	M2rwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3;udmlEPTB;MUCuN\|kxPyEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
IST-MES1	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWPJR\|UxRTFyLkS1OlQh\|ryP	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
GR-ST	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUnJR\|UxRTFyLkWwNlQh\|ryP	NWPQc5BpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SUP-T1	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfDUZJKSzVyPUGwMlc{OTdizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NB5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXO4SnhtUUN3ME2xNE46ODJ{IN88US=>	M33sOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MZ1-PC	NILrem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWjvTXdWUUN3ME2xNE46PTdzIN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-CO-1	NYnJOZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2LYW2lEPTB;MUCuPVk{OSEQvF2=	Moq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
Capan-2	NVjPbGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFP6OppKSzVyPUGxMlMyQThizszN	NUj0XJkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
697	NWD0SHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mlq5TWM2OD1zMT62O\|U4KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
REH	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYPJR\|UxRTFzLke0OVEh\|ryP	MmXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
GI-1	NVnCb3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MojJTWM2OD1zMT64OlE2KM7:TR?=	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BB65-RCC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4TkXmlEPTB;MUKuNFkyPiEQvF2=	NIrUdW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1651	NG\5R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEjWeY5KSzVyPUGyMlI1PzhizszN	MmfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1618	M4fBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYnJR\|UxRTF{LkO5O\|Yh\|ryP	Mlf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2081	NGfU[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{K1RWlEPTB;MUKuOlE1OSEQvF2=	NFfFZ3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
GCIY	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1H6bmlEPTB;MUKuO\|IyOyEQvF2=	NVHJR2xORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NY	NGHuTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3Tsd2lEPTB;MUOuNFY1OyEQvF2=	NF3I[4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
PANC-03-27	NGjEPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mmi2TWM2OD1zMz6wPFA4KM7:TR?=	NU\UVYhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BHY	NFjmRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2Hkc2lEPTB;MUOuNlEzOSEQvF2=	NXztdlNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-OV-3	NVHDTlJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTF\|LkO3OlMh\|ryP	NXO5PJl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
5637	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmnOTWM2OD1zMz63O\|U6KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LC-1F	M3jndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlS4TWM2OD1zND6wN\|U3KM7:TR?=	MnnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNB75	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MofUTWM2OD1zND6wN\|g{KM7:TR?=	M{fQTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CHP-212	MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2HlbGlEPTB;MUSuNFQ3PCEQvF2=	NGq3c\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HT-1376	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXS4W4kyUUN3ME2xOE4yOTJ4IN88US=>	M1S2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MONO-MAC-6	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEP1cJVKSzVyPUG0MlE2ODJizszN	NInyUIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CA46	M1TXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkHHTWM2OD1zND6xPFI4KM7:TR?=	Mm\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SCC-15	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\VTWM2OD1zND61OVg{KM7:TR?=	Mlq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ATN-1	NIXOSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXTJR\|UxRTF2Lk[2Nlch\|ryP	MmPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2405	NV7ZeGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfseFRKSzVyPUG0MlgyPTdizszN	M1rSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H716	NInMUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXfJR\|UxRTF2Lki0PVMh\|ryP	NYTVeYt[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW620	NFLa[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MofFTWM2OD1zND65NFE1KM7:TR?=	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H226	NWjpfmtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWjadoJVUUN3ME2xOE46ODh3IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SW962	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvvTWM2OD1zND65OFMzKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KYSE-150	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NES2UFZKSzVyPUG0Mlk2PSEQvF2=	M{PGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
OCUB-M	NVryblN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYTJR\|UxRTF2Lkm4PFMh\|ryP	M4nUe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ES7	M3XtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYTJR\|UxRTF3LkC5PFQh\|ryP	NUT0b\|JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW1463	NWHPTodbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{S5bWlEPTB;MUWuOFIzOyEQvF2=	M{foZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CAKI-1	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFXUUZFKSzVyPUG1MlU{PDZizszN	NHPDRW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MKN28	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHjmUVhKSzVyPUG1MlU1PzlizszN	MlfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW13	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3jVZpHUUN3ME2xOU43OThizszN	M3TzR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A3-KAW	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHP0fVRKSzVyPUG1Mlk3QTdizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LU-65	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYjJR\|UxRTF3Lkm3Olgh\|ryP	NGrYeoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Calu-1	M{TaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYrJR\|UxRTF4LkCzOlgh\|ryP	NFH5Xpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ST486	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXQUW1KSzVyPUG2MlA1OzFizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BB30-HNC	NWrMN3lET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEmyc3NKSzVyPUG2MlEzPDZizszN	NX;hNGFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EGI-1	M2HqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{T6cWlEPTB;MU[uOFQ3KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SH-4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGrpemtKSzVyPUG2MlQ4OzFizszN	NWT4[2tyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MN-60	MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYHJR\|UxRTF5LkKyPVch\|ryP	M1vZ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MPP-89	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX3TWmZ7UUN3ME2xO{4zPDV7IN88US=>	M1zHdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A2780	M{\yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHTF[VJKSzVyPUG3MlQyOzlizszN	NGPRXmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Daoy	M3vQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoryTWM2OD1zNz60Olk2KM7:TR?=	NH3mWG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2126	NWm5WFBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;NbmlEPTB;MUeuOFc4OSEQvF2=	NXr4SmxYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1563	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEXOd5VKSzVyPUG3MlQ6OTdizszN	NUK4[pU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
8-MG-BA	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVnJR\|UxRTF5Lk[2OFgh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
786-0	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFnW[GVKSzVyPUG3Mlg{PTNizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
AM-38	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnjuTWM2OD1zNz65N\|A3KM7:TR?=	NXTHUYVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
COLO-824	NYjpfIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU\JR\|UxRTF6LkS0N\|Yh\|ryP	M3\nfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-MEL-30	NWLjVFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIHQUIpKSzVyPUG4MlUxQDJizszN	MoDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CESS	M1WxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXnYcpJ7UUN3ME2xPE44PjB7IN88US=>	M2fPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BL-70	NWC0ZllrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NITPeoVKSzVyPUG4MlgyPTZizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2170	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHkTWM2OD1zOD65NVc6KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HT-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV3JR\|UxRTF6Lkm4N{DPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BOKU	M2fnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX3JR\|UxRTF7LkCzPFEh\|ryP	NU\CNpM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HPAF-II	NYDIS25UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYjJR\|UxRTF7LkOwNVUh\|ryP	NVfXTpFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KGN	M132eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXvJR\|UxRTF7LkS3OlUh\|ryP	M2rCNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MC-CAR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF7ITmpKSzVyPUG5MlY{OTNizszN	NGCwNVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BHT-101	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHXtXVBKSzVyPUG5Mlc4PyEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SW1783	MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2DyZWlEPTB;MUmuO\|gxPiEQvF2=	MnXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KP-N-YN	NHfjbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIP1UWdKSzVyPUKwMlAzPjJizszN	MmHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LU-165	M3vhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\VRWlEPTB;MkCuOVU4OSEQvF2=	MlHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
GOTO	NXuzNY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYrtcY5EUUN3ME2yNE43PDVzIN88US=>	NIKydok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
EFM-19	NFjLVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYPXS4k4UUN3ME2yNU4xPzF4IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CTV-1	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU\JR\|UxRTJzLkGwOVQh\|ryP	Ml\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HEL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHHHS2tKSzVyPUKxMlQzOTZizszN	M2jhXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SNU-C2B	M2K3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\3[2lEPTB;MkGuOFI3KM7:TR?=	Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ECC4	NYPvO3huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoDJTWM2OD1{MT63NFch\|ryP	NHfHbXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NEC8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHz6UHpKSzVyPUKxMlg{PjhizszN	NEfhTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KMOE-2	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYTKS3BRUUN3ME2yNU45QTJzIN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H524	NFXXUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF33RZBKSzVyPUKyMlA5ODhizszN	NHLWRW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
WSU-NHL	NV3qcYdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoTFTWM2OD1{Mj6xOVc4KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SF126	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHPPG8yUUN3ME2yNk4zPDZ7IN88US=>	M1;lWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HOP-92	NHX0V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml[1TWM2OD1{Mj6zNVY4KM7:TR?=	NEL0fpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CTB-1	NEjHVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWXJR\|UxRTJ{LkS2O\|ch\|ryP	MmP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KYSE-270	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXnnN5g5UUN3ME2yNk46OzV5IN88US=>	NUfDPHhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-MEL-24	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3vITGlEPTB;MkOuNVg4KM7:TR?=	Mm\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
Calu-3	NVK3dI9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4LUdmlEPTB;MkOuNlEzQCEQvF2=	NFjE[oE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
GAMG	NVXIZVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUfJR\|UxRTJ\|LkKzOlch\|ryP	NV7oNY9DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW1573	NUnCdYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NE\1Vm5KSzVyPUKzMlc1OTVizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	NXz6T481T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFOyWZlKSzVyPUK0MlAyQTRizszN	NFLYfpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TK10	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3W0N2lEPTB;MkSuOVAyOyEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	M{Dtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MW\JR\|UxRTJ2Lk[wOlQh\|ryP	NWn2b5piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KALS-1	NUPRfmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XKW2lEPTB;MkSuO\|MzPyEQvF2=	NFHne\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HUTU-80	NXv2fIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXPJR\|UxRTJ3LkiwN\|Ih\|ryP	MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HuP-T3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX\JR\|UxRTJ4LkG2O\|Qh\|ryP	NXnHb5dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
OE19	NXqwOFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV\NT2dvUUN3ME2yOk4zOTV\|IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
J82	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGjWfItKSzVyPUK2MlI1PzFizszN	NIrPXXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DU-4475	NXv4PZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlXuTWM2OD1{Nj6zPFE6KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DMS-53	M{m0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml;2TWM2OD1{Nj61NVM5KM7:TR?=	NUf1VpdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
COLO-741	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYPJR\|UxRTJ4LkizOFQh\|ryP	NV73XnZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW48	NH7keFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmPZTWM2OD1{Nj64PFIh\|ryP	NGmyVJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
IGR-1	M2Ts[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{DKTWlEPTB;Mk[uPVM{PCEQvF2=	NYDHOHJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
639-V	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmqyTWM2OD1{Nz6wNlQ2KM7:TR?=	M1zrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LK-2	M3fXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUe3O45zUUN3ME2yO{41OTRzIN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2347	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUT3PWV[UUN3ME2yO{46Pjl7IN88US=>	M4HQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2228	M1X6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUe2Tm5MUUN3ME2yPE4xQTB3IN88US=>	NWT3OWp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LS-123	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3nHNWlEPTB;MkiuNVI3OiEQvF2=	MnP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
U031	MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUG0dYZFUUN3ME2yPE4zPTJizszN	NX\HdlVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1792	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHHbJFwUUN3ME2yPE41PzJzIN88US=>	NF3lWZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2087	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXXJR\|UxRTJ6Lke1OVIh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2342	NHHNSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVLmOGt3UUN3ME2yPU42OjB6IN88US=>	MmniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW626	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkTZTWM2OD1{OT63OVYh\|ryP	MmjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB2518-MEL	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4nGVmlEPTB;MkmuPFE2KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
RXF393	NV3lcI9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rO[mlEPTB;M{CuNFk2OiEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LC4-1	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXjJR\|UxRTNyLkOwPVIh\|ryP	MmTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1694	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFzEWYtKSzVyPUOwMlY3OjRizszN	M2S1SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
K5	NVLGNJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXvJR\|UxRTNyLkm3NFIh\|ryP	NIfGPJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HDLM-2	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXrJR\|UxRTNyLkm3NlUh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BCPAP	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkPlTWM2OD1\|MT64N\|c6KM7:TR?=	NI\RPVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BC-3	NYTYXZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTN{LkG0NFMh\|ryP	Mn61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB996-RCC	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MW\JR\|UxRTN{LkKzOVgh\|ryP	NVXPS\|hiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2009	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MknETWM2OD1\|Mj60PVgyKM7:TR?=	NHnJNnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HTC-C3	M4PhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{LFcGlEPTB;M{OuO\|UyQSEQvF2=	NVvvdWRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LAMA-84	NGjXWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1P3eGlEPTB;M{SuOFQxPyEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	NHjHcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\ZWFhpUUN3ME2zOE42PzF3IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
AN3-CA	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXXKd4E5UUN3ME2zOU4xPTZ6IN88US=>	MkTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1734	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmnrTWM2OD1\|NT6yOVYyKM7:TR?=	NIq4e4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Ca-Ski	M3e0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXjJR\|UxRTN3LkSxNFEh\|ryP	NFPBSlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
U-266	M4[5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXfJR\|UxRTN3Lk[xNVQh\|ryP	NFv5fIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SBC-5	M3POR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\PXW9KSzVyPUO1Mlc4QDFizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GT3TKB	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIjTZZlKSzVyPUO3MlEyPSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MDA-MB-175-VII	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnzCTWM2OD1\|Nz6yNlQ5KM7:TR?=	NXX6XFVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PFSK-1	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXfJR\|UxRTN5LkK0N\|Uh\|ryP	M1XtZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
IMR-5	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\Qc2lEPTB;M{euNlQ5PyEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Daudi	M1vTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3L0OmlEPTB;M{euN\|U6PyEQvF2=	NED6eZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A498	M3nZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1;WV2lEPTB;M{euO\|IyQCEQvF2=	NU[0N5ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SCC-4	NETrUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH3xZplKSzVyPUO3Mlc5PDNizszN	MoX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-680N	M{Had2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrsTWM2OD1\|OD6yPFg2KM7:TR?=	NFfrdmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-MES-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVLJR\|UxRTN6LkOyNVUh\|ryP	MlPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SR	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn3uTWM2OD1\|OD61OFk2KM7:TR?=	NHrNbIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	NF;mPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml3ITWM2OD1\|OD61OlM4KM7:TR?=	MmXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-HEP-1	NWDXZZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3jWZWlEPTB;M{iuO\|gzOiEQvF2=	NV[yb3NZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BPH-1	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHTqXJhKSzVyPUO4Mlg{OjlizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1755	NIrnUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX3iPVVwUUN3ME2zPU42QDF5IN88US=>	MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LXF-289	NWP5S2loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF:5UYRKSzVyPUO5MlgxQDRizszN	M1XrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SW1088	NYDaXIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\XWGlEPTB;NECuNlExPyEQvF2=	M3H6[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MOLT-4	M1O4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnHNTWM2OD12MD6yPVAyKM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
AsPC-1	M4PxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFeyb\|BKSzVyPUSwMlQ2QDNizszN	NHSzNmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HOP-62	M4G0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{SxcGlEPTB;NECuOlU3QCEQvF2=	NGTvVVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A172	NEnacIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWfJR\|UxRTRyLki1NVEh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SN12C	NHf5VW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGnmWW5KSzVyPUSwMlk{QDVizszN	NUHxNogyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MDA-MB-231	NXS0WnVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYjJR\|UxRTRyLkm4PVgh\|ryP	MnLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
RPMI-2650	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmjsTWM2OD12MT6xOVk{KM7:TR?=	NISz[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-140	NEPt[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXHjSGZTUUN3ME20NU45OTJ\|IN88US=>	M4\ER\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
KINGS-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mly2TWM2OD12Mj60Olk4KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HSC-3	NGHzeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWW3bYJ7UUN3ME20Nk43PjZzIN88US=>	M1XtdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PC-14	M3TOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYn5PHBHUUN3ME20N{4yQDh{IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COR-L105	M1i5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkH0TWM2OD12Mz62OVAzKM7:TR?=	M3j2Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BE-13	NIHQU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUTJR\|UxRTR2LkKzO\|Eh\|ryP	NEDNRYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H661	M2\hUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV\adpZtUUN3ME20OE4zQTV6IN88US=>	MkTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
IST-MEL1	NHvVNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLGZo5KSzVyPUS0MlM2QTlizszN	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HCC1806	NYfxVppwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4e0fWlEPTB;NESuOVg4OyEQvF2=	M2D6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-800	NIfBOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWj1OJRCUUN3ME20OE45PDV\|IN88US=>	MkjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
IST-SL2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LRSmlEPTB;NEWuNVI1PyEQvF2=	NYDHeHVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
8305C	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\2elJKSzVyPUS1MlMxQSEQvF2=	MnvTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
UACC-62	M2r4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoTiTWM2OD12Nj6yPFc2KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COR-L23	NHnuZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkX6TWM2OD12Nz6xPVkh\|ryP	MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EFE-184	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIDNWmFKSzVyPUS3MlM5QCEQvF2=	NV;lbWMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
DMS-114	NHXzWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV;JR\|UxRTR5LkSxOFkh\|ryP	NXLlUY5NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KYSE-520	M3rLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk\FTWM2OD12OD61N\|E2KM7:TR?=	NULH[WpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNG-M	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU\tW2VrUUN3ME20PU41OzRizszN	Mo\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
A2058	NHrtRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4HjRWlEPTB;NEmuOFg5PSEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HEK293	NHfhTINHfW6ldHnvckBie3OjeR?=	M4LQO\|YxKG2rboO=	M1yzT2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigTWdHNTFicnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSCjdYTvdIhwe3Cqb4L5cIF1cW:wIITyZY5{\mWldHXkJIlvKEiHS{K5N{Bk\WyuczDwdoV1emWjdHXkJIZweiB4MDDtbY5{KG[xbHzve4VlKGK7IFnHSk0yKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDFyIH3pcpMh[nlicYXhcpRqfGG2aY\lJHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NEA:KDBwMECyPEDPxE1w	M1PwWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUWxO\|U{Lz5{Nkm1NVc2OzxxYU6=
Ba/F3	M{nPfWZ2dmO2aX;uJIF{e2G7		NIjPUHJKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGlITi1zIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyIE2gNE4xODd4IN88UU4>	M3yyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUWxO\|U{Lz5{Nkm1NVc2OzxxYU6=
HEK293	MYTGeY5kfGmxbjDhd5NigQ>?	NF\ib203OCCvaX7z	M1:ybGlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbY5{fWyrbjDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHH1eI9xcG:\|cHjvdplt[XSrb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNiZn;scI94\WRiYomgTWdHNTFic4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDxeYFvfGm2YYTpeoUhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD6wNVYh\|ryPLh?=	NH[x[Gw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm1NVc2Oyd-Mk[5OVE4PTN:L3G+
A431	MUTGeY5kfGmxbjDhd5NigQ>?		NHXhdXpKdmirYnn0bY9vKG:oIFnHSlFTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTBiPTCwMlAyQCEQvF2u	NH3Pe3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OlY2PSd-MkCzOFY3PTV:L3G+
3T3	MXzGeY5kfGmxbjDhd5NigQ>?		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGlITjGUIHX4dJJme3OnZDDpckBud3W\|ZTCzWFMh[2WubIOgZpkhTUyLU1GgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{NDFOwG0v	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ3MUiyOEc,OjF{NUG4NlQ9N2F-
NIH 3T3	NGjYZlFHfW6ldHnvckBie3OjeR?=	MXqyJIhzew>?	NGnLV5lKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIFnHSk0yWiCxdnXy[ZhxemW\|c3XkJIlvKG2xdYPlJG5KUCB\|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgTWdHOS2rbnT1Z4VlKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMjDodpMheHKrb4KgeI8hUUeIMTDpcoR2[3Srb36gcYVie3W{ZXSgZYZ1\XJiMUWgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDBwMEK0JO69VS5?	M{\uWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|IyLz5{NEmwNFczOTxxYU6=
Ba/F3	NHfxXZdHfW6ldHnvckBie3OjeR?=		MoXpTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDpcpN2dGmwIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyIE2gNE4yOjZizszNMi=>	M2\nXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUWxO\|U{Lz5{Nkm1NVc2OzxxYU6=
A673	NXzHe2tJeUiWUzDhd5NigQ>?		NF;lNHZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NX;OS5JXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NHjsUotyUFSVIHHzd4F6		NULRcoZLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NGfhc\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NGTJXnNyUFSVIHHzd4F6		M1nSV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	M3jkb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NHnaUXlyUFSVIHHzd4F6		NFHEV3VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	NYC0dVBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MVvxTHRUKGG\|c3H5		NVrWVHNbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NXLMXYptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NYrBOoQ3eUiWUzDhd5NigQ>?		NYq4[IVWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NWrCc5llRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	M2Sz[5FJXFNiYYPzZZk>		NEW1U5ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	M1rmNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MXfxTHRUKGG\|c3H5		Mn;pdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NWThSmxzeUiWUzDhd5NigQ>?		MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NFTiVItyUFSVIHHzd4F6		NXjTbYFneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	M1nuc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NH\KWVRyUFSVIHHzd4F6		M{i1VpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	NHnnOZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M{DBepFJXFNiYYPzZZk>		NXe0Z3ZIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	M3u0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP, AXL1717) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib (CP358774, NSC 718781, OSI-774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)